<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis and treatment of malnutrition in patients on maintenance hemodialysis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis and treatment of malnutrition in patients on maintenance hemodialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis and treatment of malnutrition in patients on maintenance hemodialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Srinivasan Beddhu, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Monique E Cho, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shweta Bansal, MD, FASN</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steve J Schwab, MD, FACP, FASN</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Measures of protein and energy stores such as body size [<a href="#rid1">1-7</a>], muscle mass [<a href="#rid8">8,9</a>], fat mass [<a href="#rid8">8,9</a>], serum albumin [<a href="#rid10">10-12</a>], and cholesterol [<a href="#rid13">13</a>] levels are strong predictors of survival in patients on dialysis.</p><p>In 2009, the International Society of Renal Nutrition and Metabolism (ISRNM) recommended the term protein-energy wasting (PEW) syndrome to describe the loss of body protein mass and fuel reserves in patients on dialysis [<a href="#rid14">14</a>]. The ISRNM developed objective criteria for the definition of PEW syndrome in patients on dialysis and those with chronic kidney disease (CKD) [<a href="#rid14">14</a>].</p><p>This topic reviews the pathogenesis and treatment of PEW syndrome in patients on hemodialysis.</p><p>The assessment of nutritional status and the effect of malnutrition on outcomes among patients on hemodialysis are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1850.html" rel="external">"Assessment of nutritional status in patients on hemodialysis"</a> and  <a class="medical medical_review" href="/d/html/1847.html" rel="external">"Patient survival and maintenance dialysis"</a>.)</p><p>The assessment, prevention, and treatment of malnutrition among patients on maintenance continuous peritoneal dialysis are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1855.html" rel="external">"Nutritional status and protein intake in patients on peritoneal dialysis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Protein-energy wasting (PEW) syndrome has two components, including protein (somatic, visceral, and serum) wasting and energy wasting (mainly decrease in fat stores). Although strong experimental data link inflammation, insulin resistance, and metabolic acidosis to protein wasting, it is unclear whether these mechanisms also lead to energy wasting. On the contrary, energy excess as manifested by adiposity is a major driver of inflammation and insulin resistance in patients on dialysis. Overall, the pathogenesis of PEW syndrome is incompletely understood and likely multifactorial. There have been many proposed mechanisms, but we believe these provide an incomplete explanation for the causation of PEW syndrome. Proposed mechanisms include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decreased intake and anorexia</strong> – Thirty-five to 50 percent of patients with end-stage kidney disease (ESKD) are reported to have anorexia [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1">With progression of kidney failure, there is a spontaneous decline in protein intake [<a href="#rid16">16,17</a>]. This decline likely results from the accumulation of nitrogenous waste products and increases in enteric hormones, adipokines (leptin and visfatin), and elevated inflammatory cytokines, all of which regulate appetite [<a href="#rid18">18-22</a>]. Anorexia may be worsened by depression, which is very common in patients with chronic kidney disease (CKD) and, particularly, those on dialysis.</p><p></p><p class="bulletIndent1">Among patients on hemodialysis, under-dialysis commonly causes anorexia and decreased taste acuity. In one study, an increase in dialysis dose from a Kt/V of 0.82 to 1.32 increased the protein catabolic rate (reflecting increased protein intake and better nutrition) from 0.81 to 1.02 g/kg per day over a three-month period [<a href="#rid23">23</a>]. The rise in protein catabolic rate (PCR) was likely due to improved appetite. A second group in which the dialysis regimen was unchanged had no increase in either Kt/V or PCR.</p><p></p><p class="bulletIndent1">However, an increase in dialysis beyond accepted recommended target doses does not appear to have an effect on protein intake. As an example, in the Frequent Hemodialysis Network (FHN) study, compared with conventional three times a week dialysis, more frequent dialysis did not result in an increase in protein intake as measured by equilibrated PCR [<a href="#rid24">24</a>]. Recommendations regarding dialysis dose are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis", section on 'Target Kt/V'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypercatabolic state</strong> – Some patients with CKD, particularly those on dialysis, are hypercatabolic. In one study, measured resting energy expenditure (REE) among patients with CKD (including 15 with advanced CKD, 15 on chronic hemodialysis, and 10 on peritoneal dialysis) was 10 to 20 percent higher than predicted values derived in populations without kidney disease [<a href="#rid25">25</a>]. REE was higher among both patients on peritoneal and hemodialysis compared with patients with CKD who were not on dialysis. </p><p></p><p class="bulletIndent1">However, not all patients with CKD and on dialysis are hypercatabolic. The net energy expenditure is the sum of REE plus physical activity expenditure. Many patients are sedentary, resulting in decreased physical activity expenditure [<a href="#rid26">26,27</a>]. As a result, the body mass index (BMI) of patients on incident hemodialysis has been increasing [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammation and comorbidities</strong> – The presence of an acute, chronic, or occult systemic illness may adversely affect nutritional status. Chronic lung disease, congestive heart failure, and malignancy are associated with PEW syndrome [<a href="#rid29">29</a>]. Acute illness also contributes to poor nutritional status; nutritional indices such as serum albumin are known to worsen after recent hospitalization [<a href="#rid29">29</a>]. Gastroparesis (by slowing gastric emptying) may contribute to anorexia. (See  <a class="medical medical_review" href="/d/html/2640.html" rel="external">"Gastroparesis: Etiology, clinical manifestations, and diagnosis", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1">Although the mechanism by which inflammation contributes to PEW is not clear, inflammation causes increased energy expenditure. Proinflammatory cytokine levels and oxidative stress likely contribute. (See  <a class="medical medical_review" href="/d/html/1939.html" rel="external">"Inflammation in patients with kidney function impairment"</a>.)</p><p></p><p class="bulletIndent1">In experimental models, activation of the ubiquitination pathway by inflammatory cytokines such as tumor necrosis factor (TNF)-alpha leads to proteolysis and muscle wasting [<a href="#rid30">30</a>]. A marker of nutrition, serum albumin is inversely related to the inflammatory marker, C-reactive protein (CRP) [<a href="#rid31">31</a>]. Thus, systemic inflammation could lead to protein wasting.</p><p></p><p class="bulletIndent1">It is unclear whether inflammation leads to energy wasting in dialysis patients. Indeed, despite the higher prevalence of comorbidities, higher concentrations of CRP, lower concentrations of plasma albumin, and lower muscle mass, patients on dialysis have higher BMI and higher waist circumference compared with the national norms [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1">Furthermore, adipose tissue is a major source of inflammatory cytokines, and obesity is associated with elevated CRP levels in patients with nondialysis CKD [<a href="#rid33">33</a>] and in patients on dialysis [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insulin resistance</strong> – Studies suggest that insulin resistance may contribute to muscle protein breakdown among hemodialysis patients with and without type 2 diabetes, although this has not been conclusively proven [<a href="#rid35">35,36</a>].</p><p></p><p class="bulletIndent1">The oral hypoglycemic agents that improve insulin action, such as <a class="drug drug_general" data-topicid="10249" href="/d/drug information/10249.html" rel="external">rosiglitazone</a>, ameliorate proteolysis in animal models of diabetes [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">However, while insulin resistance could lead to protein wasting, insulin resistance is primarily caused by adiposity [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic acidosis</strong> – Animal models and clinical studies of patients with CKD and those on dialysis suggest that metabolic acidosis may contribute to proteolysis and correction may provide benefit [<a href="#rid39">39-43</a>].</p><p></p><p class="bulletIndent1">As an example, in a randomized, controlled trial, peritoneal dialysis using high-lactate (40 mmol/liter) or low-lactate (35 mmol/liter) alkali dialysate was compared among 200 patients on incident continuous ambulatory peritoneal dialysis (CAPD) [<a href="#rid42">42</a>]. At one year, patients undergoing high-lactate dialysis had a greater increase in body weight (6.1±0.7 kg versus 3.7±0.6 in patients receiving low-lactate dialysis). The midarm circumference was also higher in the high-lactate group (1.26±0.16 cm versus 0.61±0.16 cm) [<a href="#rid42">42</a>]. Another randomized trial compared oral bicarbonate supplementation to standard care (ie, no supplementation) among 134 adult patients with CKD with reduced creatinine clearance (15 to 30 mL/min/1.73 m<sup>2</sup>) and metabolic acidosis (serum bicarbonate 16 to 20 mmol/L) [<a href="#rid43">43</a>]. At two years, nutritional parameters improved with bicarbonate supplementation compared with standard care [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1">However, among patients on hemodialysis, serum bicarbonate and serum creatinine (an indicator of muscle mass) are inversely correlated (ie, serum bicarbonate is high in those with decreased muscle mass) [<a href="#rid44">44</a>]. As the serum bicarbonate is already normal or high in those with low muscle mass, the role of bicarbonate supplementation on improving muscle mass in those with established PEW remains to be determined.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The dialysis procedure</strong> – The dialysis procedure itself may be catabolic due to reduced protein synthesis and the loss of amino acids in dialysate [<a href="#rid45">45,46</a>]. Amino acid losses into dialysate can average 4 to 8 g/day with peritoneal dialysis or hemodialysis [<a href="#rid47">47,48</a>]. Among patients on hemodialysis, amino acid losses may be more prominent when a bioincompatible membrane is used. (See  <a class="medical medical_review" href="/d/html/1873.html" rel="external">"Clinical consequences of hemodialysis membrane biocompatibility", section on 'Protein catabolism'</a>.)</p><p></p><p class="bulletIndent1">In addition, with hemodialysis, certain reuse procedures result in increased losses of protein into dialysate. Protein loss as high as 20 grams in one hemodialysis session has been reported with polysulfone dialyzers reused with bleach [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/d/html/1863.html" rel="external">"Reuse of dialyzers"</a>.)</p><p></p><p class="bulletIndent1">Nonetheless, more frequent dialysis does not appear to worsen nutritional indices [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary restrictions –</strong> Dietary restrictions can make food less palatable. Furthermore, fluid restriction to minimize interdialytic weight gain may lead to a decrease in caloric intake [<a href="#rid49">49</a>]. Solid food has a high fluid content, and many beverages contain a substantial amount of calories.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications –</strong> Medications, such as phosphate binders, can impair nutrient absorption.</p><p></p><p class="headingAnchor" id="H3"><span class="h1">DIETARY RECOMMENDATIONS TO PREVENT PROTEIN-ENERGY WASTING</span><span class="headingEndMark"> — </span>We agree with the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) and the European Best Practice guidelines that recommend the following diet [<a href="#rid50">50,51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>1.2 g/kg protein per day; at least 50 percent should be of high biologic value</p><p class="bulletIndent1"><span class="glyph">●</span>30 to 35 kcal/kg of calories per day</p><p></p><p>The recommended protein allowance is higher than the recommended daily allowance for healthy adults (which is 0.8 g/kg/day). These recommendations are largely based upon observational data that suggest that low protein intake is associated with increased mortality among patients on hemodialysis [<a href="#rid1">1-13</a>]. (See  <a class="medical medical_review" href="/d/html/1847.html" rel="external">"Patient survival and maintenance dialysis", section on 'Nutrition'</a>.)</p><p>However, there are no adequate randomized, controlled trials that have established that high protein or calorie intake prevents the development of protein-energy wasting (PEW) syndrome in patients on dialysis.</p><p>Among patients who do not spontaneously achieve the recommended protein intake, we do not use oral protein supplements, unless patients have specific indications, which are defined below.</p><p>In the absence of defined clinical indications, the role of nutritional supplements is unclear.</p><p>Furthermore, as body weight helps to determine the recommended protein intake (since it is defined in g/kg per day), many patients with overweight or obesity have low dietary protein intake despite adequate nutrition.</p><p>It is important to closely follow metabolic parameters (including urea) if a high protein diet is prescribed to patients on dialysis. It is conceivable that very high protein intake could be deleterious in patients on dialysis by worsening uremic toxin production [<a href="#rid52">52,53</a>], metabolic acidosis [<a href="#rid44">44</a>], and hyperphosphatemia [<a href="#rid54">54</a>].</p><p>Patients on routine hemodialysis usually have these parameters checked monthly. (See  <a class="medical medical_review" href="/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis", section on 'Patient-specific parameters'</a>.)</p><p class="headingAnchor" id="H535246994"><span class="h1">DIAGNOSIS OF PEW</span><span class="headingEndMark"> — </span>The diagnosis for protein-energy wasting (PEW) syndrome is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1850.html" rel="external">"Assessment of nutritional status in patients on hemodialysis", section on 'Diagnosis of protein-energy wasting'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">MANAGEMENT OF PEW</span><span class="headingEndMark"> — </span>Patients who have a progressive decrease in protein intake as evidenced by dietary history, protein nitrogen appearance (PNA, which is a marker for protein intake among patients on dialysis), or decline in serum albumin or who have an unintentional decrease in dry weight should have interventions to improve nutritional status. All patients should be carefully evaluated for causes of anorexia and for other possible contributors to protein-energy wasting (PEW). (See <a class="local">'Evaluate and treat comorbid conditions'</a> below.)</p><p class="headingAnchor" id="H2169210116"><span class="h2">Evaluate and treat comorbid conditions</span><span class="headingEndMark"> — </span>All patients with a history of decreased protein intake and a progressive decrease in body mass index (BMI), albumin, and PNA should be carefully evaluated. History and physical examination are essential elements of the evaluation and may reveal signs and symptoms of depression or infection that could lead to decrease in appetite [<a href="#rid55">55</a>]. Psychosocial issues such as access and affordability of food and ability to prepare meals may need intervention from the multidisciplinary team. </p><p>Patients with diabetes should be questioned regarding symptoms of gastroparesis and diarrhea, both which are common manifestations of autonomic neuropathy and could contribute to PEW syndrome. (See  <a class="medical medical_review" href="/d/html/2640.html" rel="external">"Gastroparesis: Etiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2643.html" rel="external">"Diabetic autonomic neuropathy of the gastrointestinal tract", section on 'Gastroparesis'</a> and  <a class="medical medical_review" href="/d/html/2643.html" rel="external">"Diabetic autonomic neuropathy of the gastrointestinal tract", section on 'Diabetic diarrhea'</a>.)</p><p>Insulin requirements and glycemic control should be reviewed. It is not clear whether tight control of blood sugars in patients with diabetes on hemodialysis prevents development or progression of PEW syndrome. Short-term studies suggest increased proteolysis in patients with diabetes and insulin resistance [<a href="#rid36">36,37</a>]. HbA1C goals among dialysis patients are discussed elsewhere. </p><p>It is not clear how to treat patients with overweight or obesity who have early signs of PEW syndrome. Inflammation is a major cause of muscle wasting in patients on dialysis, and adipose tissue is a site of inflammatory cytokines production. Furthermore, increased visceral fat area as measured by magnetic resonance imaging (MRI) is associated with decreased physical function [<a href="#rid56">56</a>].</p><p>It is possible that interventions targeted towards decreasing fat mass while preserving or increasing muscle mass might prevent the development of PEW syndrome in patients on dialysis [<a href="#rid57">57,58</a>]. Such interventions particularly include resistance training [<a href="#rid59">59</a>] or the use of human growth hormone [<a href="#rid60">60,61</a>].</p><p>Large randomized trials are needed to determine whether increasing physical activity in patients on dialysis with overweight or obesity decreases the development of PEW syndrome in this population.</p><p class="headingAnchor" id="H753484377"><span class="h2">Review and optimize dialysis prescription</span><span class="headingEndMark"> — </span>The dialysis prescription and achieved Kt/V should be reviewed. Among patients who are not achieving the minimum target Kt/V, we alter the dialysis prescription to provide more dialysis. Uremia resulting from insufficient dialysis decreases appetite [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis"</a>.)</p><p>Among patients who are already achieving the minimum target Kt/V, we do not increase the dialysis dose further. The maintenance of Kt/V that is higher than the accepted standard has not been shown to improve nutritional indices. This was shown in the Hemodialysis (HEMO) trial in which a high versus standard hemodialysis dose (equilibrated Kt/V 1.53±0.09 versus 1.16±0.08) did not result in improved nutritional indices [<a href="#rid62">62,63</a>]. More frequent dialysis (six times a week versus three times a week) in the Frequent Hemodialysis Network (FHN) trial also did not improve nutritional indices [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/d/html/1898.html" rel="external">"Short daily hemodialysis", section on 'Frequent Hemodialysis Network (FHN) daily trial'</a>.)</p><p class="headingAnchor" id="H1567680815"><span class="h2">Nutritional supplements</span></p><p class="headingAnchor" id="H1804347658"><span class="h3">Indications for treatment</span><span class="headingEndMark"> — </span>The following are indications for treatment with dietary supplements:</p><p class="bulletIndent1"><span class="glyph">●</span>An unintentional loss of 5 percent of nonedematous weight within three months or 10 percent of nonedematous weight over six months</p><p></p><p class="bulletIndent1"><strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An albumin &lt;3.8 g/dL</p><p></p><p>These thresholds for treatment with supplements are based on clinical judgement and experience. The effect of nutritional supplementation on clinically important outcomes is unclear. There has been only one randomized trial that examined the effects of protein supplementation on mortality in patients on dialysis [<a href="#rid65">65</a>]. However, that study compared intradialytic <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> with oral protein supplement and did not include a usual care arm [<a href="#rid65">65</a>]. In both groups, PNA increased along with an increase in body weight and serum albumin, but there were no differences between the two groups regarding the primary endpoint of mortality [<a href="#rid65">65</a>]. A 2020 Cochrane review including 22 randomized trials that examined oral protein-based nutritional supplements in patients on maintenance dialysis concluded that supplementation likely increased serum albumin, especially in patients on hemodialysis and those with malnutrition, and may have increased serum prealbumin and mid-arm muscle circumference [<a href="#rid66">66</a>].</p><p>Two large, observational studies of oral nutritional supplement suggested better survival associated with nutritional supplement [<a href="#rid67">67,68</a>]. Protein supplementation was associated with a 29 percent decreased mortality over a mean follow-up of 14 months (hazard ratio [HR] 0.71, 95% CI 0.58-0.86). However, in both studies, residual confounding related to patient-, or facility-related factors cannot be excluded. In addition, the mechanism underlying benefit is not clear; an obvious effect of supplementation on the serum albumin concentration, muscle mass, or protein anabolism has not been conclusively demonstrated [<a href="#rid26">26,65,69-78</a>].</p><p class="headingAnchor" id="H3634653332"><span class="h3">Our approach</span><span class="headingEndMark"> — </span>For most patients selected for treatment with dietary supplements, we suggest oral supplements rather than intravenous supplements. For most patients on hemodialysis, intradialytic <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> (IDPN) and oral supplements are equally effective. In one comparative study, 186 patients on hemodialysis patients with malnutrition were randomly assigned to oral nutritional supplements, with or without one year of IDPN [<a href="#rid65">65</a>]. At two years, there was no difference in mortality, hospitalization rate, and nutritional status between the two groups. Specific oral agents are discussed below. (See <a class="local">'Oral supplements'</a> below.)</p><p>However, for patients who continue to lose weight or have very low serum albumin (&lt;3.2 g/dL) despite oral supplementation for three months, we use IDPN, providing the patient can consume at least 50 percent of the prescribed caloric intake [<a href="#rid51">51</a>]. (See <a class="local">'Intradialytic parenteral nutrition'</a> below.)</p><p>If this degree of oral intake cannot be reached, we may try a nasoenteral feeding tube with nighttime enteral nutrition or, if oral intake is not tolerated, institute total <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> (TPN) [<a href="#rid79">79</a>]. However, most of the patients with malnutrition resistant to both oral supplements and IDPN have an underlying terminal illness such as metastatic malignancy or advanced heart failure. In such patients, options including TPN, withdrawal of dialysis, or comfort care measures should be discussed. (See  <a class="medical medical_review" href="/d/html/1626.html" rel="external">"Nutrition support in intubated critically ill adult patients: Parenteral nutrition"</a> and  <a class="medical medical_review" href="/d/html/1877.html" rel="external">"Kidney palliative care: Withdrawal of dialysis", section on 'Indications for withdrawal of dialysis'</a>.)</p><p>We do not treat patients with dietary supplements who do not have the specific indications listed above. (See <a class="local">'Indications for treatment'</a> above.)</p><p>In the absence of specific indications, we believe that many patients on dialysis (who often have higher than optimal BMI and waist circumference) do not have PEW syndrome. We believe the reason that many studies did not show a benefit of protein supplementation on nutritional markers may have because patients included in the study did not have PEW syndrome. By contrast, in studies where the BMI was low [<a href="#rid65">65,71</a>] or serum albumin was low [<a href="#rid65">65,70,71</a>], protein supplementation was effective in increasing serum albumin and body weight.</p><p class="headingAnchor" id="H925539471"><span class="h3">Oral supplements</span><span class="headingEndMark"> — </span>For most patients selected for treatment with dietary supplements, we use oral supplements.</p><p>Several supplements are formulated specifically for patients with end-stage kidney disease (ESKD) and are low in potassium and dense in nutrients, which provides adequate calories and protein and minimizes the risk of hyperkalemia and fluid overload. However, these supplements are more costly than less specific preparations, which often decreases compliance. Our selection of a specific agent depends on patient characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span>Among patients who have no history of interdialytic hyperkalemia or volume overload (and are able to tolerate the increase in potassium and fluid intake), we use general supplements such as Ensure or Boost Nutritional Drink because of their low cost.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients who have a history of hyperkalemia or volume overload on dialysis (due, for example, to heart failure), we use a specific "kidney failure" supplement, such as Novasource Renal or Nepro, which have double the calorie and protein and 30 to 35 percent less potassium and phosphorus content per mL of supplement.</p><p></p><p>A different regimen is required in patients with severe anorexia who are unable to increase their oral intake. Overnight supplementation by nasoenteral feeding tube may be effective in this setting [<a href="#rid80">80,81</a>]. A short course of overnight tube feeding can lead to a sufficient improvement in nutritional status and overall wellbeing so that adequate dietary oral can be resumed.</p><p>We do not prescribe oral essential amino acids, although some evidence suggests that the administration of essential amino acids may be modestly beneficial to patients with significant hypoalbuminemia [<a href="#rid70">70,82</a>]. Further study is needed prior to any recommendation concerning their use.</p><p class="headingAnchor" id="H2790159261"><span class="h3">Intradialytic parenteral nutrition</span><span class="headingEndMark"> — </span>For patients who continue to lose weight or have very low serum albumin (&lt;3.2 g/dL) despite oral supplementation and for patients such as those with severe gastroparesis who may be unable to tolerate oral supplementation, we use IDPN.</p><p>IDPN is convenient because it is delivered during dialysis and is likely to be beneficial in some patients [<a href="#rid83">83</a>]. However, although a number of case reports and studies suggest that IDPN provides substantial benefit, the studies were mostly retrospective or poorly designed [<a href="#rid79">79,84,85</a>].</p><p>IDPN is the most costly and least efficient nutritional supplement. IDPN often costs twice as much as dialysis itself, and only 70 percent of the nutrients are actually delivered to the patient because of loss into the dialysate [<a href="#rid86">86</a>].</p><p>In addition, IDPN may provide insufficient protein and calories to treat PEW syndrome since IDPN is administered only three days per week for approximately four hours [<a href="#rid80">80</a>]. As noted above, we do not use IDPN for hemodialysis patient who cannot consume at least 50 percent of the prescribed caloric intake [<a href="#rid51">51</a>]. (See <a class="local">'Our approach'</a> above.)</p><p>IDPN solutions are similar to those used for TPN. (See  <a class="medical medical_review" href="/d/html/1626.html" rel="external">"Nutrition support in intubated critically ill adult patients: Parenteral nutrition", section on 'Composition'</a>.)</p><p>A typical solution contains 10 percent amino acids and 40 to 50 percent glucose, 10 to 20 percent lipids, or a mixture of carbohydrate or lipids, depending upon the needs of the patient.</p><p>IDPN may be associated with a lower than expected delivered dose of dialysis due, possibly, to increased urea generation [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H11"><span class="h3">Experimental methods</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9456" href="/d/drug information/9456.html" rel="external">Recombinant human growth hormone</a>, androgenic anabolic steroids, antiinflammatory drugs, and zinc have been studied in patients on dialysis with PEW. We do not use any of these agents for routine clinical use:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human growth hormone </strong>–<strong> </strong>Some studies suggest that administration of <a class="drug drug_general" data-topicid="9456" href="/d/drug information/9456.html" rel="external">recombinant human growth hormone</a> can reduce wasting and catabolism, improve nutritional status, and lower the blood urea nitrogen (BUN) in patients on hemodialysis [<a href="#rid60">60,61,88-93</a>]. The benefit from recombinant human growth hormone may be mediated by an increase in free insulin-like growth factor-1 (IGF-1) levels [<a href="#rid94">94,95</a>].</p><p></p><p class="bulletIndent1">However, significant long-term nutritional benefits with human growth hormone are not consistently observed [<a href="#rid96">96</a>], and effects of this costly agent on malnutrition-associated morbidity and mortality are unclear [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1">The OPPORTUNITY randomized trial was designed to assess the effect of human growth hormone on survival but was prematurely terminated because of slow recruitment [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Androgenic anabolic steroids </strong>–<strong> </strong>Limited data are available on the effects of androgenic anabolic steroids among patients on dialysis [<a href="#rid98">98-100</a>]. Although increases in body weight, muscle mass, and serum albumin have been reported, the long-term efficacy and risk for adverse effects is unclear. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiinflammatory agents </strong>–<strong> </strong>The use of antiinflammatory agents in patients with malnutrition-inflammation syndrome complex is reviewed separately. (See  <a class="medical medical_review" href="/d/html/1939.html" rel="external">"Inflammation in patients with kidney function impairment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Zinc – </strong>Patients on dialysis often have decreased taste acuity, which is controversially associated with zinc deficiency [<a href="#rid101">101</a>]. The role of zinc deficiency has never been established.</p><p></p><p class="headingAnchor" id="H20738456"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16439.html" rel="external">"Patient education: Dialysis and diet (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protein-energy wasting syndrome</strong> – Patients on hemodialysis are commonly depleted of protein and energy stores as a result of either deficient nutrition or protein and energy wasting. The term protein-energy wasting (PEW) syndrome describes the loss of body protein mass and fuel reserves in patients with end-stage kidney disease (ESKD). PEW syndrome is associated with a poor prognosis. (See <a class="local">'Introduction'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis of PEW</strong> – The pathogenesis of PEW is incompletely understood and likely multifactorial. There have been many proposed mechanisms, but all provide an incomplete explanation for the causation of PEW syndrome. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary recommendations to prevent PEW</strong> – Dietary recommendations for patients on hemodialysis include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>1.2 g/kg protein per day; at least 50 percent should be of high biologic value</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>30 to 35 kcal/kg of calories per day (see <a class="local">'Dietary recommendations to prevent protein-energy wasting'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of PEW</strong> – Patients with a history of decreased protein intake and any evidence of progressive decrease in body mass index (BMI), albumin, and protein nitrogen appearance (PNA) should be carefully evaluated for cause. Comorbidities and under-dialysis, both which could contribute to anorexia should be addressed. (See <a class="local">'Evaluate and treat comorbid conditions'</a> above and <a class="local">'Review and optimize dialysis prescription'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for nutritional supplementation</strong> – Indications for treatment with dietary supplements include an unintentional loss of 5 percent of nonedematous weight within three months or 10 percent of nonedematous weight over six months or an albumin &lt;3.8 g/dL. (See <a class="local">'Indications for treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Types of nutritional supplementation</strong> – For most patients selected for treatment with dietary supplements, we suggest oral supplements rather than intravenous supplements (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Oral supplementation is safe, equally effective as, and less costly than intravenous supplementation. An exception is patients who continue to lose weight or have very low serum albumin (&lt;3.2 g/dL) despite oral supplementation for three months; for such patients, we use intradialytic <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> (IDPN), providing the patient can consume at least 50 percent of the prescribed caloric intake. (See <a class="local">'Our approach'</a> above and <a class="local">'Oral supplements'</a> above and <a class="local">'Intradialytic parenteral nutrition'</a> above.)</p><p></p><p class="headingAnchor" id="H2101671957"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Marsha Wolfson, MD, FACP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Abbott KC, Glanton CW, Trespalacios FC, et al. Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int 2004; 65:597.</a></li><li><a class="nounderline abstract_t">Beddhu S, Pappas LM, Ramkumar N, Samore M. Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 2003; 14:2366.</a></li><li><a class="nounderline abstract_t">Kalantar-Zadeh K, Abbott KC, Salahudeen AK, et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81:543.</a></li><li><a class="nounderline abstract_t">Kalantar-Zadeh K, Streja E, Kovesdy CP, et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc 2010; 85:991.</a></li><li><a class="nounderline abstract_t">Port FK, Ashby VB, Dhingra RK, et al. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 2002; 13:1061.</a></li><li><a class="nounderline abstract_t">Johansen KL, Young B, Kaysen GA, Chertow GM. Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr 2004; 80:324.</a></li><li><a class="nounderline abstract_t">Kopple JD, Zhu X, Lew NL, Lowrie EG. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int 1999; 56:1136.</a></li><li><a class="nounderline abstract_t">Huang CX, Tighiouart H, Beddhu S, et al. Both low muscle mass and low fat are associated with higher all-cause mortality in hemodialysis patients. Kidney Int 2010; 77:624.</a></li><li><a class="nounderline abstract_t">Kakiya R, Shoji T, Tsujimoto Y, et al. Body fat mass and lean mass as predictors of survival in hemodialysis patients. Kidney Int 2006; 70:549.</a></li><li><a class="nounderline abstract_t">Owen WF Jr, Lew NL, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329:1001.</a></li><li><a class="nounderline abstract_t">Kimmel PL, Chawla LS, Amarasinghe A, et al. Anthropometric measures, cytokines and survival in haemodialysis patients. Nephrol Dial Transplant 2003; 18:326.</a></li><li><a class="nounderline abstract_t">Kopple JD. Nutritional status as a predictor of morbidity and mortality in maintenance dialysis patients. ASAIO J 1997; 43:246.</a></li><li><a class="nounderline abstract_t">Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63:793.</a></li><li><a class="nounderline abstract_t">Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73:391.</a></li><li><a class="nounderline abstract_t">Bossola M, Tazza L, Giungi S, Luciani G. Anorexia in hemodialysis patients: an update. Kidney Int 2006; 70:417.</a></li><li><a class="nounderline abstract_t">Kopple JD, Berg R, Houser H, et al. Nutritional status of patients with different levels of chronic renal insufficiency. Modification of Diet in Renal Disease (MDRD) Study Group. Kidney Int Suppl 1989; 27:S184.</a></li><li><a class="nounderline abstract_t">Duenhas MR, Draibe SA, Avesani CM, et al. Influence of renal function on spontaneous dietary intake and on nutritional status of chronic renal insufficiency patients. Eur J Clin Nutr 2003; 57:1473.</a></li><li><a class="nounderline abstract_t">Wright M, Woodrow G, O'Brien S, et al. Cholecystokinin and leptin: their influence upon the eating behaviour and nutrient intake of dialysis patients. Nephrol Dial Transplant 2004; 19:133.</a></li><li><a class="nounderline abstract_t">Muscaritoli M, Molfino A, Chiappini MG, et al. Anorexia in hemodialysis patients: the possible role of des-acyl ghrelin. Am J Nephrol 2007; 27:360.</a></li><li><a class="nounderline abstract_t">Cheung W, Yu PX, Little BM, et al. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005; 115:1659.</a></li><li><a class="nounderline abstract_t">Carrero JJ, Witasp A, Stenvinkel P, et al. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol Dial Transplant 2010; 25:901.</a></li><li><a class="nounderline abstract_t">Kalantar-Zadeh K, Block G, McAllister CJ, et al. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80:299.</a></li><li><a class="nounderline abstract_t">Lindsay RM, Spanner E, Heidenheim RP, et al. Which comes first, Kt/V or PCR--chicken or egg? Kidney Int Suppl 1992; 38:S32.</a></li><li><a class="nounderline abstract_t">Kaysen GA, Greene T, Larive B, et al. The effect of frequent hemodialysis on nutrition and body composition: frequent Hemodialysis Network Trial. Kidney Int 2012; 82:90.</a></li><li><a class="nounderline abstract_t">Neyra R, Chen KY, Sun M, et al. Increased resting energy expenditure in patients with end-stage renal disease. JPEN J Parenter Enteral Nutr 2003; 27:36.</a></li><li><a class="nounderline abstract_t">Beddhu S, Wei G, Marcus RL, et al. Light-intensity physical activities and mortality in the United States general population and CKD subpopulation. Clin J Am Soc Nephrol 2015; 10:1145.</a></li><li><a class="nounderline abstract_t">Anderton N, Giri A, Wei G, et al. Sedentary Behavior in Individuals With Diabetic Chronic Kidney Disease and Maintenance Hemodialysis. J Ren Nutr 2015; 25:364.</a></li><li><a class="nounderline abstract_t">Kramer HJ, Saranathan A, Luke A, et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17:1453.</a></li><li><a class="nounderline abstract_t">Thijssen S, Wong MM, Usvyat LA, et al. Nutritional Competence and Resilience among Hemodialysis Patients in the Setting of Dialysis Initiation and Hospitalization. Clin J Am Soc Nephrol 2015; 10:1593.</a></li><li><a class="nounderline abstract_t">Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996; 335:1897.</a></li><li><a class="nounderline abstract_t">Kaysen GA, Dubin JA, Müller HG, et al. Impact of albumin synthesis rate and the acute phase response in the dual regulation of fibrinogen levels in hemodialysis patients. Kidney Int 2003; 63:315.</a></li><li><a class="nounderline abstract_t">Beddhu S, Filipowicz R, Chen X, et al. Supervised oral protein supplementation during dialysis in patients with elevated C-reactive protein levels: a two phase, longitudinal, single center, open labeled study. BMC Nephrol 2015; 16:87.</a></li><li><a class="nounderline abstract_t">Ramkumar N, Cheung AK, Pappas LM, et al. Association of obesity with inflammation in chronic kidney disease: a cross-sectional study. J Ren Nutr 2004; 14:201.</a></li><li><a class="nounderline abstract_t">Axelsson J, Heimbürger O, Lindholm B, Stenvinkel P. Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr 2005; 15:131.</a></li><li><a class="nounderline abstract_t">Pupim LB, Flakoll PJ, Majchrzak KM, et al. Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. Kidney Int 2005; 68:1857.</a></li><li><a class="nounderline abstract_t">Siew ED, Pupim LB, Majchrzak KM, et al. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 2007; 71:146.</a></li><li><a class="nounderline abstract_t">Wang X, Hu Z, Hu J, et al. Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 2006; 147:4160.</a></li><li><a class="nounderline abstract_t">Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271:665.</a></li><li><a class="nounderline abstract_t">Bailey JL, Wang X, England BK, et al. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 1996; 97:1447.</a></li><li><a class="nounderline abstract_t">Reaich D, Channon SM, Scrimgeour CM, et al. Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation. Am J Physiol 1993; 265:E230.</a></li><li><a class="nounderline abstract_t">Graham KA, Reaich D, Channon SM, et al. Correction of acidosis in hemodialysis decreases whole-body protein degradation. J Am Soc Nephrol 1997; 8:632.</a></li><li><a class="nounderline abstract_t">Stein A, Moorhouse J, Iles-Smith H, et al. Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int 1997; 52:1089.</a></li><li><a class="nounderline abstract_t">de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009; 20:2075.</a></li><li><a class="nounderline abstract_t">Kaysen GA, Greene T, Daugirdas JT, et al. Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients. Am J Kidney Dis 2003; 42:1200.</a></li><li><a class="nounderline abstract_t">Ikizler TA, Pupim LB, Brouillette JR, et al. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am J Physiol Endocrinol Metab 2002; 282:E107.</a></li><li><a class="nounderline abstract_t">Ikizler TA. Effects of hemodialysis on protein metabolism. J Ren Nutr 2005; 15:39.</a></li><li><a class="nounderline abstract_t">Blumenkrantz MJ, Gahl GM, Kopple JD, et al. Protein losses during peritoneal dialysis. Kidney Int 1981; 19:593.</a></li><li><a class="nounderline abstract_t">Ikizler TA, Flakoll PJ, Parker RA, Hakim RM. Amino acid and albumin losses during hemodialysis. Kidney Int 1994; 46:830.</a></li><li><a class="nounderline abstract_t">Sherman RA, Cody RP, Rogers ME, Solanchick JC. Interdialytic weight gain and nutritional parameters in chronic hemodialysis patients. Am J Kidney Dis 1995; 25:579.</a></li><li><a class="nounderline abstract_t">Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000; 35:S1.</a></li><li><a class="nounderline abstract_t">Tattersall J, Martin-Malo A, Pedrini L, et al. EBPG guideline on dialysis strategies. Nephrol Dial Transplant 2007; 22 Suppl 2:ii5.</a></li><li><a class="nounderline abstract_t">Mitch WE, Remuzzi G. Diets for patients with chronic kidney disease, still worth prescribing. J Am Soc Nephrol 2004; 15:234.</a></li><li><a class="nounderline abstract_t">Marzocco S, Dal Piaz F, Di Micco L, et al. Very low protein diet reduces indoxyl sulfate levels in chronic kidney disease. Blood Purif 2013; 35:196.</a></li><li><a class="nounderline abstract_t">Streja E, Lau WL, Goldstein L, et al. Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients. Kidney Int Suppl (2011) 2013; 3:462.</a></li><li><a class="nounderline abstract_t">Cohen SD, Norris L, Acquaviva K, et al. Screening, diagnosis, and treatment of depression in patients with end-stage renal disease. Clin J Am Soc Nephrol 2007; 2:1332.</a></li><li><a class="nounderline abstract_t">Martinson M, Ikizler TA, Morrell G, et al. Associations of body size and body composition with functional ability and quality of life in hemodialysis patients. Clin J Am Soc Nephrol 2014; 9:1082.</a></li><li><a class="nounderline abstract_t">van den Ham EC, Kooman JP, Schols AM, et al. The functional, metabolic, and anabolic responses to exercise training in renal transplant and hemodialysis patients. Transplantation 2007; 83:1059.</a></li><li><a class="nounderline abstract_t">Kopple JD, Wang H, Casaburi R, et al. Exercise in maintenance hemodialysis patients induces transcriptional changes in genes favoring anabolic muscle. J Am Soc Nephrol 2007; 18:2975.</a></li><li><a class="nounderline abstract_t">Castaneda C, Gordon PL, Parker RC, et al. Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. Am J Kidney Dis 2004; 43:607.</a></li><li><a class="nounderline abstract_t">Johannsson G, Bengtsson BA, Ahlmén J. Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Am J Kidney Dis 1999; 33:709.</a></li><li><a class="nounderline abstract_t">Feldt-Rasmussen B, Lange M, Sulowicz W, et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol 2007; 18:2161.</a></li><li><a class="nounderline abstract_t">Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.</a></li><li><a class="nounderline abstract_t">Rocco MV, Dwyer JT, Larive B, et al. The effect of dialysis dose and membrane flux on nutritional parameters in hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65:2321.</a></li><li><a class="nounderline abstract_t">FHN Trial Group, Chertow GM, Levin NW, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363:2287.</a></li><li><a class="nounderline abstract_t">Cano NJ, Fouque D, Roth H, et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J Am Soc Nephrol 2007; 18:2583.</a></li><li><a class="nounderline abstract_t">Mah JY, Choy SW, Roberts MA, et al. Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev 2020; 5:CD012616.</a></li><li><a class="nounderline abstract_t">Lacson E Jr, Wang W, Zebrowski B, et al. Outcomes associated with intradialytic oral nutritional supplements in patients undergoing maintenance hemodialysis: a quality improvement report. Am J Kidney Dis 2012; 60:591.</a></li><li><a class="nounderline abstract_t">Weiner DE, Tighiouart H, Ladik V, et al. Oral intradialytic nutritional supplement use and mortality in hemodialysis patients. Am J Kidney Dis 2014; 63:276.</a></li><li><a class="nounderline abstract_t">Caglar K, Fedje L, Dimmitt R, et al. Therapeutic effects of oral nutritional supplementation during hemodialysis. Kidney Int 2002; 62:1054.</a></li><li><a class="nounderline abstract_t">Eustace JA, Coresh J, Kutchey C, et al. Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia. Kidney Int 2000; 57:2527.</a></li><li><a class="nounderline abstract_t">Hiroshige K, Sonta T, Suda T, et al. Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic haemodialysis. Nephrol Dial Transplant 2001; 16:1856.</a></li><li><a class="nounderline abstract_t">Leon JB, Albert JM, Gilchrist G, et al. Improving albumin levels among hemodialysis patients: a community-based randomized controlled trial. Am J Kidney Dis 2006; 48:28.</a></li><li><a class="nounderline abstract_t">Kalantar-Zadeh K, Braglia A, Chow J, et al. An anti-inflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: a pilot/feasibility study. J Ren Nutr 2005; 15:318.</a></li><li><a class="nounderline abstract_t">Bronich L, Te T, Shetye K, et al. Successful treatment of hypoalbuminemic hemodialysis patients with a modified regimen of oral essential amino acids. J Ren Nutr 2001; 11:194.</a></li><li><a class="nounderline abstract_t">Oğuz Y, Bulucu F, Vural A. Oral and parenteral essential amino acid therapy in malnourished hemodialysis patients. Nephron 2001; 89:224.</a></li><li><a class="nounderline abstract_t">Moretti HD, Johnson AM, Keeling-Hathaway TJ. Effects of protein supplementation in chronic hemodialysis and peritoneal dialysis patients. J Ren Nutr 2009; 19:298.</a></li><li><a class="nounderline abstract_t">Fouque D, McKenzie J, de Mutsert R, et al. Use of a renal-specific oral supplement by haemodialysis patients with low protein intake does not increase the need for phosphate binders and may prevent a decline in nutritional status and quality of life. Nephrol Dial Transplant 2008; 23:2902.</a></li><li><a class="nounderline abstract_t">Pupim LB, Majchrzak KM, Flakoll PJ, Ikizler TA. Intradialytic oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status. J Am Soc Nephrol 2006; 17:3149.</a></li><li><a class="nounderline abstract_t">Wolfson M. Use of intradialytic parenteral nutrition in hemodialysis patients. Am J Kidney Dis 1994; 23:856.</a></li><li><a class="nounderline abstract_t">Kopple JD. Therapeutic approaches to malnutrition in chronic dialysis patients: the different modalities of nutritional support. Am J Kidney Dis 1999; 33:180.</a></li><li><a class="nounderline abstract_t">Abras E, Walser M. Nitrogen utilization in uremic patients fed by continuous nasogastric infusion. Kidney Int 1982; 22:392.</a></li><li><a class="nounderline abstract_t">Bossola M, Muscaritoli M, Tazza L, et al. Malnutrition in hemodialysis patients: what therapy? Am J Kidney Dis 2005; 46:371.</a></li><li><a class="nounderline abstract_t">Pupim LB, Flakoll PJ, Brouillette JR, et al. Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. J Clin Invest 2002; 110:483.</a></li><li><a class="nounderline abstract_t">Foulks CJ. An evidence-based evaluation of intradialytic parenteral nutrition. Am J Kidney Dis 1999; 33:186.</a></li><li><a class="nounderline abstract_t">Capelli JP, Kushner H, Camiscioli TC, et al. Effect of intradialytic parenteral nutrition on mortality rates in end-stage renal disease care. Am J Kidney Dis 1994; 23:808.</a></li><li><a class="nounderline abstract_t">Wolfson M, Jones MR, Kopple JD. Amino acid losses during hemodialysis with infusion of amino acids and glucose. Kidney Int 1982; 21:500.</a></li><li><a class="nounderline abstract_t">McCann L, Feldman C, Hornberger J, et al. Effect of intradialytic parenteral nutrition on delivered Kt/V. Am J Kidney Dis 1999; 33:1131.</a></li><li><a class="nounderline abstract_t">Ziegler TR, Lazarus JM, Young LS, et al. Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. J Am Soc Nephrol 1991; 2:1130.</a></li><li><a class="nounderline abstract_t">Ikizler TA, Wingard RL, Breyer JA, et al. Short-term effects of recombinant human growth hormone in CAPD patients. Kidney Int 1994; 46:1178.</a></li><li><a class="nounderline abstract_t">Ikizler TA, Wingard RL, Hakim RM. Interventions to treat malnutrition in dialysis patients: the role of the dose of dialysis, intradialytic parenteral nutrition, and growth hormone. Am J Kidney Dis 1995; 26:256.</a></li><li><a class="nounderline abstract_t">Fouque D, Peng SC, Shamir E, Kopple JD. Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients. Kidney Int 2000; 57:646.</a></li><li><a class="nounderline abstract_t">Hansen TB, Gram J, Jensen PB, et al. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study. Clin Nephrol 2000; 53:99.</a></li><li><a class="nounderline abstract_t">Garibotto G, Barreca A, Sofia A, et al. Effects of growth hormone on leptin metabolism and energy expenditure in hemodialysis patients with protein-calorie malnutrition. J Am Soc Nephrol 2000; 11:2106.</a></li><li><a class="nounderline abstract_t">Garibotto G, Barreca A, Russo R, et al. Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. J Clin Invest 1997; 99:97.</a></li><li><a class="nounderline abstract_t">Iglesias P, Díez JJ, Fernández-Reyes MJ, et al. Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. Am J Kidney Dis 1998; 32:454.</a></li><li><a class="nounderline abstract_t">Kotzmann H, Schmidt A, Lercher P, et al. One-year growth hormone therapy improves granulocyte function without major effects on nutritional and anthropometric parameters in malnourished hemodialysis patients. Nephron Clin Pract 2003; 93:C75.</a></li><li><a class="nounderline abstract_t">Kopple JD, Cheung AK, Christiansen JS, et al. OPPORTUNITY&amp;trade;: a large-scale randomized clinical trial of growth hormone in hemodialysis patients. Nephrol Dial Transplant 2011; 26:4095.</a></li><li><a class="nounderline abstract_t">Gascón A, Belvis JJ, Berisa F, et al. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. Geriatr Nephrol Urol 1999; 9:67.</a></li><li><a class="nounderline abstract_t">Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999; 281:1275.</a></li><li><a class="nounderline abstract_t">Barton Pai A, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. Clin Nephrol 2002; 58:38.</a></li><li><a class="nounderline abstract_t">Atkin-Thor E, Goddard BW, O'Nion J, et al. Hypogeusia and zinc depletion in chronic dialysis patients. Am J Clin Nutr 1978; 31:1948.</a></li></ol></div><div id="topicVersionRevision">Topic 1856 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14717930" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12937315" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effects of body size and body composition on survival in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755821" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Survival advantages of obesity in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21037042" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11912267" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277152" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Association of body size with outcomes among patients beginning dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10469384" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Body weight-for-height relationships predict mortality in maintenance hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20072111" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Both low muscle mass and low fat are associated with higher all-cause mortality in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16788699" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Body fat mass and lean mass as predictors of survival in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8366899" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12543888" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Anthropometric measures, cytokines and survival in haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9152503" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nutritional status as a predictor of morbidity and mortality in maintenance dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631061" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094682" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16775598" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Anorexia in hemodialysis patients: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2636655" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Nutritional status of patients with different levels of chronic renal insufficiency. Modification of Diet in Renal Disease (MDRD) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14576761" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Influence of renal function on spontaneous dietary intake and on nutritional status of chronic renal insufficiency patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671048" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cholecystokinin and leptin: their influence upon the eating behaviour and nutrient intake of dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17556836" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Anorexia in hemodialysis patients: the possible role of des-acyl ghrelin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15931394" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Role of leptin and melanocortin signaling in uremia-associated cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19948877" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277149" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1405378" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Which comes first, Kt/V or PCR--chicken or egg?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22456602" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The effect of frequent hemodialysis on nutrition and body composition: frequent Hemodialysis Network Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12549596" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Increased resting energy expenditure in patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25931456" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Light-intensity physical activities and mortality in the United States general population and CKD subpopulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25753603" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sedentary Behavior in Individuals With Diabetic Chronic Kidney Disease and Maintenance Hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16597682" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Increasing body mass index and obesity in the incident ESRD population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26185260" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Nutritional Competence and Resilience among Hemodialysis Patients in the Setting of Dialysis Initiation and Hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8948566" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472798" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Impact of albumin synthesis rate and the acute phase response in the dual regulation of fibrinogen levels in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26099512" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Supervised oral protein supplementation during dialysis in patients with elevated C-reactive protein levels: a two phase, longitudinal, single center, open labeled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15483779" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Association of obesity with inflammation in chronic kidney disease: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15648022" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Adipose tissue and its relation to inflammation: the role of adipokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16164664" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17063174" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16777975" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8571133" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8617877" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8396331" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10495793" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Correction of acidosis in hemodialysis decreases whole-body protein degradation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9328950" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Role of an improvement in acid-base status and nutrition in CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19608703" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Bicarbonate supplementation slows progression of CKD and improves nutritional status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655192" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739090" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15648005" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of hemodialysis on protein metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7241892" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Protein losses during peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7996804" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Amino acid and albumin losses during hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7702053" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Interdialytic weight gain and nutritional parameters in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10895784" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17507427" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : EBPG guideline on dialysis strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14694178" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Diets for patients with chronic kidney disease, still worth prescribing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23485887" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Very low protein diet reduces indoxyl sulfate levels in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25019031" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17942763" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Screening, diagnosis, and treatment of depression in patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24763868" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Associations of body size and body composition with functional ability and quality of life in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17452896" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The functional, metabolic, and anabolic responses to exercise training in renal transplant and hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17942969" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Exercise in maintenance hemodialysis patients induces transcriptional changes in genes favoring anabolic muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15042537" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10196013" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17554147" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12490682" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of dialysis dose and membrane flux in maintenance hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15149346" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The effect of dialysis dose and membrane flux on nutritional parameters in hemodialysis patients: results of the HEMO Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21091062" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : In-center hemodialysis six times per week versus three times per week.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17656473" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32390133" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22632807" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Outcomes associated with intradialytic oral nutritional supplements in patients undergoing maintenance hemodialysis: a quality improvement report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24094606" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Oral intradialytic nutritional supplement use and mortality in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12164890" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Therapeutic effects of oral nutritional supplementation during hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10844622" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11522870" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16797384" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Improving albumin levels among hemodialysis patients: a community-based randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16007562" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : An anti-inflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: a pilot/feasibility study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11679999" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Successful treatment of hypoalbuminemic hemodialysis patients with a modified regimen of oral essential amino acids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11549907" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Oral and parenteral essential amino acid therapy in malnourished hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19539184" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effects of protein supplementation in chronic hemodialysis and peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18408077" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Use of a renal-specific oral supplement by haemodialysis patients with low protein intake does not increase the need for phosphate binders and may prevent a decline in nutritional status and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17021267" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Intradialytic oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8203368" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Use of intradialytic parenteral nutrition in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9915288" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Therapeutic approaches to malnutrition in chronic dialysis patients: the different modalities of nutritional support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6816982" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Nitrogen utilization in uremic patients fed by continuous nasogastric infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129199" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Malnutrition in hemodialysis patients: what therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12189242" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9915289" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : An evidence-based evaluation of intradialytic parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8203363" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effect of intradialytic parenteral nutrition on mortality rates in end-stage renal disease care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7087285" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Amino acid losses during hemodialysis with infusion of amino acids and glucose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10352202" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effect of intradialytic parenteral nutrition on delivered Kt/V.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1777593" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7861714" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Short-term effects of recombinant human growth hormone in CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7611260" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Interventions to treat malnutrition in dialysis patients: the role of the dose of dialysis, intradialytic parenteral nutrition, and growth hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10652043" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10711411" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11053487" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Effects of growth hormone on leptin metabolism and energy expenditure in hemodialysis patients with protein-calorie malnutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9011582" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9740162" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12616034" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : One-year growth hormone therapy improves granulocyte function without major effects on nutritional and anthropometric parameters in malnourished hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21750157" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : OPPORTUNITY&amp;trade;: a large-scale randomized clinical trial of growth hormone in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10518249" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10208142" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12141405" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/707353" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Hypogeusia and zinc depletion in chronic dialysis patients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
